TIANJIN TIANYAO PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.35 CNY | +3.82% |
|
+6.36% | -11.22% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.69B 511M | Sales 2023 | 3.78B 524M | Capitalization | 5.36B 742M |
|---|---|---|---|---|---|
| Net income 2022 | 35M 4.84M | Net income 2023 | 117M 16.19M | EV / Sales 2022 | 1.52 x |
| Net Debt 2022 | 756M 105M | Net Debt 2023 | 233M 32.26M | EV / Sales 2023 | 1.48 x |
| P/E ratio 2022 |
138
x | P/E ratio 2023 |
45.8
x | Employees | 2,678 |
| Yield 2022 |
0.23% | Yield 2023 |
1.78% | Free-Float | 42.94% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.82% | ||
| 1 week | +6.36% | ||
| Current month | +6.36% | ||
| 1 month | +9.85% | ||
| 3 months | +21.17% | ||
| 6 months | -15.86% | ||
| Current year | -11.22% |
1 week
4.13
4.46
1 month
3.584.46
Current year
3.105.09
1 year
3.106.26
3 years
3.106.26
5 years
3.106.26
10 years
3.1013.29
| Managers | Title | Age | Since |
|---|---|---|---|
Shu Xiang Li
CEO | Chief Executive Officer | 52 | 22-06-09 |
Juan Li
BRD | Director/Board Member | 44 | 20-11-12 |
| 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hua Xu
CHM | Chairman | 58 | 22-11-17 |
Wei Zhao
CHM | Chairman | 55 | 23-09-21 |
Yong Yan Chi
BRD | Director/Board Member | 51 | 19-07-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 4.35 | +3.82% | 19,139,200 |
| 24-05-07 | 4.19 | +0.48% | 9,989,931 |
| 24-05-06 | 4.17 | +1.96% | 9,759,800 |
| 24-04-30 | 4.09 | +1.49% | 10,646,400 |
End-of-day quote Shanghai S.E., May 07, 2024
More quotes
Jinyao Pharmaceutical Co Ltd, formerly Tianjin Tianyao Pharmaceuticals Co., Ltd., is a China-based company mainly engaged in the research and development, production and sales of corticosteroids and amino acid APIs and preparations. The Company's main products include dexamethasone series, prednisone series, methylprednisolone series, betamethasone series and more than 40 varieties of corticosteroid raw materials, 23 varieties of amino acid raw materials, and 16 dosage forms such as tablets, injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, and inhalation preparations. The Company mainly operates in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.22% | 635M | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B |
- Stock Market
- Equities
- 600488 Stock